Kenvue (KVUE) to Release Quarterly Earnings on Thursday

Posted by on Jul 13th, 2023

Kenvue (NYSE:KVUE – Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, July 20th. Analysts expect Kenvue to post earnings of $0.29 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Kenvue Stock Up 0.7 %

KVUE stock opened at $25.25 on Thursday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.00 and a current ratio of 1.53. Kenvue has a one year low of $24.75 and a one year high of $27.80. The firm’s 50 day moving average price is $25.97.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of research analyst reports. UBS Group initiated coverage on Kenvue in a research report on Tuesday, May 30th. They issued a “neutral” rating and a $28.00 target price on the stock. HSBC initiated coverage on Kenvue in a research report on Thursday, June 1st. They issued a “hold” rating and a $27.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on Kenvue in a research report on Monday, May 29th. They issued an “overweight” rating and a $29.00 target price on the stock. The Goldman Sachs Group initiated coverage on Kenvue in a research report on Tuesday, May 30th. They issued a “neutral” rating and a $29.00 target price on the stock. Finally, BNP Paribas began coverage on Kenvue in a research report on Tuesday, May 30th. They issued a “neutral” rating and a $28.00 target price on the stock. Six analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus price target of $28.33.

Insider Transactions at Kenvue

In other news, Director Richard E. Allison, Jr. bought 20,000 shares of the stock in a transaction that occurred on Thursday, May 11th. The stock was purchased at an average price of $26.26 per share, for a total transaction of $525,200.00. Following the completion of the purchase, the director now owns 20,000 shares in the company, valued at approximately $525,200. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kenvue Company Profile

(Get Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.

Read More

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.